Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$19.97M$19.97Mderived+86.1% vs Q4 2024 Net Income-$108.04M-$108.04MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$121,578,000N/M Operating Cash Flowderived-$96,213,000N/M Free Cash Flowderived-$97,333,000N/M Margins · derivedOperating margin-608.9%+556.4 pt vs Q4 2024
Net margin-541.1%+358.5 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 12, 2026 · 43 d after period end